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ABSTRACT 
 
New 1,5-benzothiazepin-4-(5H)-one derivatives (9a-9e) have been synthesized. The anti-angiogenic and anti-
oxidant properties of the new derivatives were then evaluated. All the compounds (9a-9e) exhibited very good 
inhibition of capillary proliferation, thus proving their anti-angiogenic properties. In addition, the in vitro 
antioxidant activities of these compounds were evaluated using diphenyl picryl hydrazine (DPPH), and NO (nitric 
oxide) assays, and the results were compared with butylated hydroxytoluene (BHT), a well known anti-oxidant. 
Compounds (9a-9e) showed excellent free-radical scavenging activities in the nitric oxide assay, thus proving to be 
more potent than BHT. 
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INTRODUCTION 
 
1,5-benzothiazepines have potential chemotherapeutic importance as calcium channel blockers [1] anticancer [2], 
antihypertensive [3], antibacterial [4] agents, anti-HIV [5] and  anti-hypertensive. [6] Some of the wellknown drugs 
are thiazesim (fig 1) [7] is used as an antidepressant, diltiazem and clentiazem (fig 1) [8, 9] are a well known angina-
relieving calcium channel blocker. 
 
Figure 1: Examples of well known 1,5-benzothiazepines drugs 
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Angiogenesis is the development of new blood vessels from pre-existing vasculatures and this has been well 
recognized as an essential hallmark for the growth, invasion and metastasis of tumors. [10] Deregulation of 
angiogenesis under pathological conditions causes several diseases like diabetic retinopathy, rheumatoid arthritis, 
and cancer. [11] Thus, the inhibition of tumor angiogenesis provides a therapeutic strategy for treating different 
types of cancers. In many cases anti-angiogenic agents act as cytostatics and prevent the growth of tumors, though it 
is thought that they can be made more successful in cancer chemotherapy by combining with cytotoxic agents. [12] 
 
Antioxidants are molecules inhibiting the oxidation of other molecules thereby preventing the cell death that occurs 
due to the release of free radicals. Reactive oxygen species generated in the cell during anti-oxidation initiate and 
promote tumor growth as well as other degenerative diseases such as heart attacks, strokes, arthritis and cataracts. 
[13] Minimizing oxidative damage may be an important approach to the primary treatment of these diseases, since 
antioxidants prevent the free radical formation, or interrupt an oxidizing chain reaction. Thus, antioxidants can be 
regarded as important factors for the treatment of cancer. Compounds functioning with groups endowed with 
potential antioxidant properties are considered as new drugs for chemoprevention and chemotherapy. [14] 
Therefore, the development of synthetic compounds, capable of scavenging free radicals, has been a great interest. 
 
In continuation of our work on development of synthetic methodologies for bioactive molecules, [15,16] our 
previous work on synthesis and biological activities novel 1,5-benzothiazepin-4(5H)-one derivatives [17] prompted 
us to extend the work to synthesize and test the  antioxidant and antiangiogenic activities  of 1,5-benzothiazepin-
4(5H)-one analogues. 
 
EXPERIMENTAL SECTION 
 
1.1 Materials and methods 
All reagents were purchased from Sigma Aldrich Chemicals. Infrared (IR) spectra were recorded on a JASCO 
FT/IR-4100 spectrophotometer in KBr disc for solid compounds and nujol for liquids and are reported in reciprocal 
wave number (cm-1). 1H NMR spectra were recorded in DMSO-d6 at 300 and 400 MHz. The following 
abbreviations are used for structural assignments of 1H NMR: s, singlet; d, doublet; t, triplet; dd, doublet of 
doublets; m, multiplet and br, broad. Mass and purity were recorded on a LC–MSD-Trap-XCT. Thin layer 
chromatography was performed using 600 mesh silica gel plates, and visualization was effected with short 
wavelength UV light (254 nm). All other commercial reagents were used as received. 
 
1.2  Biological activities 
1.2.1 Antioxidant activities 
1.2.1.1 DPPH radical scavenging assay 
DPPH radical scavenging activity was carried out according to the method of Scherer et al. [18] Briefly, DPPH 
solution (1 mL, 0.1 mM in 95% ethanol) was mixed with different aliquots of (9a-9e). After vigorous shaking, the 
mixture was allowed to stand for 20 min at room temperature. Absorbance of the resulting solution was measured at 
517 nm with a UV-VIS spectrophotometer (HITACHI, U-2900). Butylated hydroxyl toluene (BHT) was used as 
positive control. Radical scavenging potential is expressed as IC50 value, which represents the sample concentration 
at which 50 % of DPPH radicals are scavenged. Briefly, DPPH solution (1 mL, 0.1 mM in 95% ethanol) was mixed 
with different aliquots of (9a-9e). After vigorous shaking, the mixture was allowed to stand for 20 min at room 
temperature. Absorbance of the resulting solution was measured at 517 nm with a UV-VIS spectrophotometer 
(HITACHI, U-2900). Butylated hydroxyl toluene (BHT) was used as positive control. Radical scavenging potential 
is expressed as IC50 value, which represents the sample concentration at which 50 % of DPPH radicals are 
scavenged. 
 
1.2.1.2 Nitric oxide radical scavenging activity 
Under physiological conditions, nitric oxide (NO) plays important roles as a neurotransmitter, vasodilator and in the 
immunological system it fights against tumor cells and infectious agents. During inflammatory reactions, NO is 
produced by the inducible enzyme NO synthase (iNOS) in cells like macrophages, hepatocytes, and renal cells after 
stimulation by lipopolysaccharide (LPS), tumor necrosis factor (TNF-α), interleukin (IL-1) or interferon (INF-γ), 
and acts as a defense and regulatory signal molecule. However, NO is pathogenic when present in excess, as it is a 
reactive radical itself, and directly damages normal tissues.26 Further, NO can also react with superoxide anion 
radical to form the even stronger oxidant, peroxynitrite.27 Among the samples studied, (9a-9e) showed highly 
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significant (P < 0.01) activity in scavenging NO radical with IC50 values of 83.4 and 106.4 µg/mL, respectively, 
when compared to 51.79 µg/mL recorded for BHT (Table 1). 
 
1.2.2 Antiangiogenic activity 
Fertilized eggs were obtained from IVRI, Bangalore, India. All chemicals were purchased from Sisco Research 
Laboratories, Mumbai, India and they were of analytical grade. Antiangiogenic effects of (9a-9e) compounds was 
studied according to the method of Auerbach et a,[19] Briefly, fertilized hens eggs were surface sterilized using 70% 
alcohol. The eggs were incubated in fan assisted humidified incubator at 37 ºC. On the 4th day, the eggs were 
cracked out into thin films of the hammock within a laminar flow cabinet and were further incubated. On day 5th 
when blood vessels were seen proliferating from the center of the eggs within the hammock, filter paper discs loaded 
with 100 µg of the compounds (9a-9e) were placed over the proliferating blood vessels and the eggs were returned 
to the incubator. Results of antiangiogenic effects of the compounds were noted after 24 h. 
 
1.3 Synthetic method 
 Scheme 1: 1,5-benzothiazepin-4(5H)-one derivatives 
 
Reagents: (a) DIBAL-H, NaBH4; (b) NaOH, MeOH; (c) HBr, con. H2SO4; (d) aq.KOH, 4, THF; (e) T3P, Et3N; (f) NBS, AIBN 60 oC, 6h; (g) 
Na2CO3 (aq), tetrakis, Pd(dppf), 120 oC, 12h. 
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Figure 2: Structures of synthesized 1,5-benzothiazepin-4(5H)-one derivatives 
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1.3.1 Synthetic procedure 
In these synthetic protocol compounds 1-7 were synthesized by using standard procedure of our research work [20]. 
 
Step-1: Procedure for the synthesis of Ethyl-[2-n-butyl-2-hydroxy methyl] hexanoate (2) 
Diethyl di-n-butyl malonate (25 g, 0.09 mol) was dissolved in toluene (142.8 ml) under N2 atmosphere and cooled to 
-60 to -70 oC. DIBAL-H (25% in toluene, 31.32 g, 0.22 mol) solution was added at this temperature for 4 h, stirred 
for 15min. Absolute ethanol (176.76 ml) was added slowly at -40 to -50 oC and the temperature was raised to 0 oC. 
NaBH4 (3.49 g, 0.09 mol) was added portion wise below 0 oC and the reaction mixture was stirred at room 
temperature for one hour, cooled to 15 – 20 oC and saturated Na2SO4 solution was added. The reaction mass was 
stirred for an hour, filtered through celite bed, extracted with ethyl acetate (25×2), washed with brine, dried over 
sodium sulfate and concentrated under vacuum at 50-55 oC to afford the title compound 2 as thick syrup. 
 
Pale yellow liquid, yield 19.0 g, 76%; FT-IR (Paraffin) υ/cm-1 : 3617, 2857, 1739; 1H NMR (400MHz, DMSO-d6): δ 
= 4.56(t, 1H, J=4.8), 4.01(q, 2H, J=7.2), 3.42(d, 2H, J=5.2), 1.36-1.49(m, 8H), 1.18(t, 4H, J=7.2),  0.80(t, 6H, J= 
8.6); MS (ES) m/z (m+1) : 244.3 
 
Step 2: General procedure for the synthesis of Ethyl-[2-n-butyl-2-hydroxy methyl] hexanoic acid (3) 
To a stirred solution of Ethyl-[2-n-butyl-2-hydroxy methyl] hexanoate (15 g, 0.0652 mol) in methanol (67.5 ml), 
NaOH (5.86 g, 0.146 mol) solution was added and refluxed for 17hrs. Distilled off the methanol at 55-60 oC under 
vacuum, cooled to room temperature and washed with petroleum ether. Aqueous layer was taken back to the reactor, 
cooled to 10-15 oC and acidified with concentrated HCl to get pH 2. Extracted with dichloromethane (25×2) and 
washed with brine solution. Organic layer was dried over sodium sulfate and concentrated under vacuum at 40 – 45 
oC to yield thick syrup. 
 
Pale yellow liquid, yield 13.73, 92%; FT-IR(Paraffin) υ/cm-1 : 2857, 3359, 2857; 1H NMR (400MHz, DMSO-d6): δ 
= 11.94(s, 1H), 3.40(d, 2H, J=4.8), 1.34-1.46(m, 8H), 1.24(t, 4H, J=7.2), 0.80(t, 6H, J= 8.6); MS (ES) m/z(m+1) : 
203.3 
 
Step 3: General procedure for the synthesis of 2-bromomethyl-2-n-butyl hexanoic acid (4)  
To a solution of 48% aq. hydrobromic acid con. H2SO4 was added slowly at below 25 oC over a period of 1h and 
then added 2 (10 g, 0.049 mol). The reaction mixture was heated to 90-95 oC and maintained at this temperature for 
16 h and cooled to 15-20 oC. Extracted the reaction mixture with dichloromethane (25×2). Organic layer was 
concentrated under vacuum at 40 – 45 oC, residue was distilled using high vacuum pump. Product distills at 140-160 
oC at 1mm pressure. 
 
Pale yellow liquid, yield 4.36 g, 35%; FT-IR(Paraffin) υ/cm-1 : 2857, 2923, 512; 1H NMR (400MHz, DMSO-d6): δ = 
12.62(s, 1H), 3.58(s, 1H), 1.46-1.59(m, 4H), 1.19-1.28(m, 8H), 0.80(t, 6H, J= 8.6); MS (ES) m/z(m+1) : 266.2 
 
Step 5: General procedure for the synthesis of 2-{[(2-amino-5-methoxyphenyl)thio]methyl}-2-n-butyl hexanoic 
acid (6) 
To a stirred solution of amino-6-methoxy benzothiazole (4 g, 0.022 mol) in water (44 ml) was added KOH (12.4 g, 
0.22 mol). Refluxed the reaction mixture for 16 h under N2 atmosphere. Cooled to 15 oC and added 3 (7.63 g, 0.028 
mol) in THF (9.48 ml) slowly over a period of 30 min and then allowed the reaction mass to come to 20-25 oC and 
stirred for 10 h and then refluxed at 60-65 oC for 2 h. Cooled to 20-25 oC and diluted with water. Adjusted the pH of 
the reaction to 5 using 1.5N HCl, diluted with water and extracted with DCM (25×2). Organic layer was washed 
with water and then with brine solution and dried over sodium sulfate and solvent was removed under reduced 
pressure to yield a thick syrup.  
 
Dark brown liquid, yield 3.6 g, 90%; FT-IR(Paraffin) υ/cm-1 : 3363, 3189, 2923, 2857 1H NMR (400MHz, DMSO-
d6): δ = 6.83(s, 1H), 6.64(dd, 2H, J=2.8, 0.4), 3.60(s, 3H), 2.95(s, 2H), 1.48-1.56(m, 4H), 1.13(t, 4H, J=6.4), 1.20(t, 
4H, J=5.6), 0.80(t, 6H, J= 8.6); MS (ES) m/z(m+1)= 340.3 
 
Step 6: General procedure for the synthesis of 3,3-di-n-butyl-8-methoxy-2,3-dihydro-1,5-benzothiazepin-
4(5H)one (7) 
To a stirred solution of 4 (3 g, 0.0088 mol) in ethyl acetate (27 ml), was added triethyl amine (1.95g, 0.0193 mol). 
Cooled to 0 oC and added T3P (2.81 g, 0.0088 mol) at 0 oC. Stirred at 25 oC for 3 h and diluted with ethyl acetate. 
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Washed the above organic layer with 10% NaHCO3 solution and then washed with water and brine and dried over 
sodium sulfate and concentrated under vacuum at 50 oC to obtain crude product which was purified on silica gel 
using ethyl acetate and hexane. 
 
Brown solid, yield 3.6 g, 90%; FT-IR(KBr) υ/cm-1 : 3092, 2867, 1213, 1644,1H NMR (400MHz, DMSO-d6): δ 
=9.48(s, 1H), 7.00(d, 1H, J=8.4), 6.93(d, 1H, J=2.8), 6.82(q, 1H, J=2.8), 3.69(s, 3H), 2.94(s, 2H), 1.39-1.46(m, 4H), 
1.14-1.39(m, 8H), 0.80(t, 6H, J= 8.6); MS (ES) m/z(m+1)= 322.0 
 
Step 7: Synthesis of bromo derivative of 1,5-benzothiazepin-4(5H)-one (8) 
To stirred solution of 7,(2g, 6.22 mmol)  in DCM/acetonitrile (10 vol 1:1 ratio), was cooled to 5 oC and added N-
bromosuccinimide (1.32g, 7.42 mmol) over a period of 15 mins. Brought the reaction mixture temperature to 25 oC, 
stirred for 2 hours and cooled to -5 oC for 1 hour, filtered, washed with cold acetonitrile and then dried under 
vacuum to yield an off white solid. 
 
Off white solid, yield 4.5 g, 87%; FT-IR(KBr) υ/cm-1 : 3087, 2865, 1221, 1639,1H NMR (400MHz, DMSO-d6): δ 
=9.57(s, 1H), 7.29 (d, 1H), 7.07(s, 1H), 3.79(s, 3H), 2.95(s, 2H), 1.42-1.63(m, 4H), 1.14-1.40(m, 8H), 0.81(t, 6H, J= 
8.6); MS (ES) m/z(m+2)= 400.0 
 
Step 8: General procedure foe synthesis of 1,5-benzothiazepin-4(5H)-one derivatives (9a-9e) 
A solution of bromo indazole 8 (0.4 g, 1 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride 
[Pd(dppf)Cl2] (10%) in anhydrous DME (10 mL) was stirred under a flow of argon for 1 h. To the solution were 
added sequentially corresponding boronic (2 mmol) in anhydrous DME (2.6 mL) and potassium carbonate (2 mmol) 
in water (2.5 mL). The mixture was heated to 80 °C for 2 h and allowed to cool. The reaction mixture was then 
poured into aqueous saturated NaHCO3 solution and extracted with ethyl acetate. The organic layers were combined, 
washed with brine and dried over Na2SO4. The solution was concentrated in vacuo and the residue was purified by 
flash column chromatography on silica gel to give the desired product. 
 
9a: White solid, yield 4.5 g, 87%; FT-IR(KBr) υ/cm-1 : 3099, 2866, 1218, 1649,1H NMR (400MHz, DMSO-d6): δ 
=9.48(s, 1H), 7.52 (d, 2H, J=7.6), 7.50(d, 2H, J=7.6), 7.42(t, 1H, J=7.8), 7.27(s, 1H), 7.09(s, 1H), 3.81(s, 3H), 
3.01(s, 2H), 1.44-1.61(m, 4H), 1.15-1.44(m, 8H), 0.80(t, 6H, J= 8.6); MS (ES) m/z(m+1)= 398.34 
 
9b: Off white solid, yield 4.5 g, 87%; FT-IR(KBr) υ/cm-1 : 3094, 2872, 1210, 1651,1H NMR (400MHz, DMSO-d6): 
δ =9.54(s, 1H), 7.78 (d, 2H, J=7.6), 7.52(d, 2H, J=7.8), 7.30(s, 1H), 7.10(s, 1H), 3.78(s, 3H), 2.98(s, 2H), 1.42-
1.63(m, 4H); MS (ES) m/z(m+1)= 433.18 
9c: Off white solid, yield 4.5 g, 87%; FT-IR(KBr) υ/cm-1 : 3087, 2872, 1217, 1644,1H NMR (400MHz, DMSO-d6): 
δ =9.51(s, 1H), 9.18(s, 1H),  8.69 (d, 1H, J=7.8), 7.32(s, 1H), 7.12(s, 1H), 3.83(s, 3H), 2.99(s, 2H); MS (ES) 
m/z(m+1)= 399.74 
 
9d: Off white solid, yield 4.5 g, 87%; FT-IR(KBr) υ/cm-1 : 3096, 2870, 1310, 1216, 1651,1H NMR (400MHz, 
DMSO-d6): δ =9.49(s, 1H), 7.62 (d, 2H, J=7.6), 7.30 (s, 1H), 7.12 (s, 1H), 7.06 (d, 2H, J=7.6), 3.89 (s, 1H), 3.84 (s, 
1H), 2.98(s, 2H); MS (ES) m/z(m+1)= 428.45 
 
9e: Off white solid, yield 4.5 g, 87%; FT-IR(KBr) υ/cm-1 : 3089, 2877, 1218, 1654,1H NMR (400MHz, DMSO-d6): 
δ =9.58(s, 1H), 7.69 (s, 1H), 7.39 (t, 1H, J=7.8), 7.30 (d, 1H, J=7.6), 7.25 (s, 1H), 7.18 (d, 1H, J=7.6), 7.11 (s, 1H); 
MS (ES) m/z(m+1)= 412.34 
 
RESULTS AND DISCUSSION 
 
1.4.1 Antioxidant activities 
Antioxidants are characterized by their ability to scavenge free radicals. The antioxidant properties of 1,5-
benzothiazepin-4(5H)one analogues against various free radicals were investigated and compared with that of BHT 
at five concentration levels. The values of IC50, and the effective concentration at which 50% of the radicals were 
scavenged were calculated. Lower IC50 value demonstrated greater antioxidant activity. IC50 value of BHT was also 
measured for comparison. The results are tabulated in Table 1.  
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All the compounds (9a-9e) showed enhanced antioxidant activities compared to BHT with nitric oxide assay at 
different concentrations (20-100 µg/mL), although these analogues exhibited low interaction with DPPH at 20-
100µg/mL concentrations.  
 
Table 1: Free radical scavenging activity of the compounds (9a-9e) 
 
Compounds IC50 values(µg/ml) 
 DPPH NO 
7 145.4 96.2 
8 179.9 102.3 
9d 162.3 98.76 
9b 174.3 106.4 
9a 138.4 99.2 
9e 168.7 103.2 
9c 118.3 83.4 
BHT 51.79 121.48 
 
1.4.2 Antiangiogenic activity 
Antiangiogenic treatment is one of the main methods of tumor treatment and control of pathological angiogenesis. 
[20] Pathological angiogenesis is regulated by targeting integrins which are predominantly expressed in most of the 
tumor cells and endothelial cells of blood vessels. The blocking of the vascular endothelial growth factor (VEGF) 
and its receptors in a signal transduction pathway also regulates angiogenesis. [21] 
 
In the present investigation, all the compounds (9a-9e) showed a reduced proliferation of blood vessels in the shell 
less CAM assay model of developing embryos. The proliferation of microvessels was regressed in all treated group 
(9a-9e) (Figure 1) supporting their antiangiogenic activity.   
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Figure 2: Inhibition of angiogenesis in vivo of 1,5-benzothiazepin-4-(5H)-ones (9a–9e) in shell- less CAM assay 
 
CONCLUSION 
 
In this research work, new 1,5-benzothiazepin-4(5H)-one derivatives have been synthesized and their antioxidant 
and antiangiogenic activities have been assessed. Oxidative stress and angiogenesis are important biological 
mechanisms by which tumorgenesis and tumor progression occur. Antiangiogenic determined in the shell-less CAM 
model revealed that 9a-9e compounds are endowed with interesting anti-tumor activities. Further, antioxidants have 
proved to protect against oncogenic transformations resulting from radiation and free-radicals in experimental 
systems. The significant multiple antioxidant activities of 1,5-benzothiazepin-4(5H)-one derivatives, especially the 
high nitric oxide radical scavenging activity of 9a-9e, appear to protect the cells by neutralizing or trapping reactive 
oxygen species and other free radicals. From this study, this can be concluded that rational design of 1,5-
benzothiazepin-4(5H)-one derivatives can be developed to create useful anti-angiogenic and antioxidant agents that 
could lead further research work on this potent nucleus. 
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